Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 1 of 19 PageID: 3908
`
`
`
`Eric I. Abraham
`Christy L. Saveriano
`HILL WALLACK LLP
`202 Carnegie Center
`Princeton, New Jersey 08540
`Telephone: (609) 924-0808
`Fax: (609) 452-1888
`Attorneys for Defendant
`ACS Dobfar Info SA
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`Civil Action No. 1:13-cv-05723-NLH-
`AMD
`
`
`
`
`
`
`
`CHIESI USA INC.,
`CORNERSTONE BIOPHARMA, INC., and
`EKR THERAPEUTICS, LLC,
`
`Plaintiffs,
`
`v.
`
`
`SANDOZ INC., SANDOZ AG, and
`ACS DOBFAR INFO SA
`
`Defendants.
`
`SANDOZ INC.
`
`Counterclaim-Plaintiff,
`
`v.
`
`
`CHIESI USA INC.,
`CORNERSTONE BIOPHARMA, INC., and
`EKR THERAPEUTICS, LLC
`
`Counterclaim-Defendants.
`
`ACS DOBFAR INFO SA ANSWER TO PLAINTIFFS’ AMENDED COMPLAINT
`
`Defendant ACS Dobfar Info SA (“Dobfar”), by and through its undersigned attorneys,
`
`hereby answers each of the numbered paragraphs of the Amended Complaint by Chiesi USA,
`
`Inc. (“Chiesi USA,” formerly known as Cornerstone Therapeutics Inc.), Cornerstone BioPharma,
`
`Inc. (“Cornerstone BioPharma”), and EKR Therapeutics, LLC (“EKR,” collectively “Plaintiffs”).
`
`ny-1154439
`
`EKR Therapeutics, LLC Exhibit 2007 Page 1
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 2 of 19 PageID: 3909
`
`
`
`Except as expressly admitted below, Dobfar denies each and every allegation of Plaintiffs’
`
`Amended Complaint.
`
`1.
`
`Answering paragraph 1 of the Amended Complaint, Dobfar denies each and every
`
`allegation therein, except Dobfar admits that this is an action for patent infringement purportedly
`
`arising under the patent laws of the United States, Title 35 of the United States Code, involving
`
`United States Patent Nos. 7,612,102 (the “’102 Patent”), 7,659,291 (the “’291 Patent”),
`
`8,455,524 (the “’524 Patent”), and 7,659,290 (the “’290 Patent”, collectively with the ’102, ’291
`
`and ’524 Patents, the “Patents-in-Suit”). Dobfar further admits that purported copies of the ’102,
`
`’291, ’524, and ’290 Patents are attached as Exhibits A-D, respectively, to the Amended
`
`Complaint.
`
`2.
`
`Answering Paragraph 2 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief as to the truth of the allegations in
`
`Paragraph 2 and therefore denies each and every allegation therein.
`
`3.
`
`Answering Paragraph 3 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief as to the truth of the allegations in
`
`Paragraph 3 and therefore denies each and every allegation therein.
`
`4.
`
`Answering Paragraph 4 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief as to the truth of the allegations in
`
`Paragraph 4 and therefore denies each and every allegation therein.
`
`5.
`
`Answering Paragraph 5 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 5 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`
`ny-1154439
`
`- 2 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 2
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 3 of 19 PageID: 3910
`
`
`
`6.
`
`Answering Paragraph 6 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 6 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`7.
`
`Answering Paragraph 7 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 7 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`8.
`
`Answering Paragraph 8 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 8 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`9.
`
`Answering Paragraph 9 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 9 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`10.
`
`Answering Paragraph 10 of the Amended Complaint, Dobfar admits that it has a
`
`place of business at ACS Dobfar Info SA, Casai, CH- 7748 Campascio, Switzerland.
`
`11.
`
`Answering Paragraph 11 of the Amended Complaint, Dobfar states that
`
`Paragraph 11 consists entirely of legal conclusions that do not require a response, and denies
`
`each and every allegation therein to which a response is required, but states that it does not
`
`contest that subject matter jurisdiction is proper pursuant to 28 U.S.C. §§ 1331 and 1338(a) with
`
`respect to Plaintiffs’ claims regarding the ’102, ’291, and ’524 Patents under 35 U.S.C. §
`
`271(e)(2)(A). Dobfar specifically denies all other allegations of subject matter jurisdiction under
`
`any other sub-paragraphs of 35 U.S.C. § 271, and further denies that this Court has the subject
`
`matter jurisdiction over the ’290 Patent.
`
`
`ny-1154439
`
`- 3 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 3
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 4 of 19 PageID: 3911
`
`
`
`12.
`
`Answering Paragraph 12 of the Amended Complaint, Dobfar states that
`
`Paragraph 12 consists entirely of legal conclusions that do not require a response and further
`
`states that the allegations of Paragraph 12 are directed to another Defendant and therefore require
`
`no response from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`13.
`
`Answering Paragraph 13 of the Amended Complaint, Dobfar states that
`
`Paragraph 13 consists entirely of legal conclusions that do not require a response, and denies
`
`each and every allegation therein to which a response is required, except admits: (1) Dobfar
`
`entered into a Manufacture and Supply Agreement with Sandoz AG, the content of which speaks
`
`for itself and (2) that in the matter of Novartis Pharm. Corp. v. Actavis LLC, Civ. No. 13-1028
`
`(D.N.J.) Dobfar stated that “Dobfar admits, for purposes of this action only, that the Court has
`
`personal jurisdiction over Dobfar.” (Civ. No. 13-1028, Dkt. No. 223.)
`
`14.
`
`Answering Paragraph 14 of the Amended Complaint, Dobfar states that
`
`Paragraph 14 consists entirely of legal conclusions that do not require a response, and denies the
`
`allegations of Paragraph 14.
`
`15.
`
`Answering Paragraph 15 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief about the truth of the allegations in
`
`Paragraph 15 and therefore denies them.
`
`16.
`
`Answering Paragraph 16 of the Amended Complaint, Dobfar denies the
`
`allegations therein, except admits that the ’102 Patent is entitled “Pre-mixed, Ready-to-Use
`
`Pharmaceutical Compositions,” and that the ’102 Patent states on its face that it was issued on
`
`November 3, 2009.
`
`17.
`
`Answering Paragraph 17 of the Amended Complaint, Dobfar denies the
`
`allegations therein, except admits that the ’291 Patent is entitled “Methods of Treatment with
`
`
`ny-1154439
`
`- 4 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 4
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 5 of 19 PageID: 3912
`
`
`
`Pre-Mixed, Ready-to-Use Pharmaceutical Compositions,” and that the ’291 Patent states on its
`
`face that it was issued on February 9, 2010.
`
`18.
`
`Answering Paragraph 18 of the Amended Complaint, Dobfar denies the
`
`allegations therein, except admits that the ’524 Patent is entitled “Methods of Treatment with
`
`Pre-Mixed, Ready-to-Use Pharmaceutical Compositions,” and that the ’524 Patent states on its
`
`face that it was issued on June 4, 2013.
`
`19.
`
`Answering Paragraph 19 of the Amended Complaint, Dobfar denies the
`
`allegations therein, except admits that the ’290 Patent is entitled “Methods of Preparing Pre-
`
`Mixed, Ready-to-Use Pharmaceutical Compositions,” that the ’290 Patent states on its face that
`
`it was issued on February 9, 2010, that the face of the ’290 Patent lists U.S. Patent Application
`
`No. 12/407,551 as the patent application from which the ’290 Patent issued, and states that the
`
`12/407,551 application is a division of U.S. Patent Application No. 11/788,076.
`
`20.
`
`Answering Paragraph 20 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief about the truth of the allegations in
`
`Paragraph 20 and therefore denies them, except admits that the face of each Patent-in-Suit states
`
`that it claims priority to U.S. Provisional Application No. 60/793,074.
`
`21.
`
`Answering Paragraph 21 of the Amended Complaint, Dobfar states that it lacks
`
`knowledge or information sufficient to form a belief about the truth of the allegations in
`
`Paragraph 21 and therefore denies them, except Dobfar admits that the ’102 Patent, the ’291
`
`Patent, and the ’524 Patent are listed in FDA’s publication titled “Approved Drug Products with
`
`Therapeutic Equivalence Evaluations” (commonly known as the “Orange Book”).
`
`22.
`
`Answering Paragraph 22 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 22 are directed to another Defendant and therefore require no response
`
`
`ny-1154439
`
`- 5 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 5
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 6 of 19 PageID: 3913
`
`
`
`from Dobfar. Dobfar objects that the allegations in Paragraph 22 are not “simple, concise, and
`
`direct” as required under Federal Rule of Civil Procedure 8(d)(1) and, on that basis, denies the
`
`allegations of Paragraph 22. To the extent that a response by Dobfar is required, Dobfar denies
`
`the allegations of Paragraph 22, except on information and belief, Dobfar admits that ANDA
`
`203978 was filed and that the ANDA seeks FDA approval of the drug products described
`
`therein.
`
`23.
`
`Answering Paragraph 23 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 23.
`
`24.
`
`Answering Paragraph 24 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 24, except admits that Sandoz AG and Dobfar entered into the
`
`Manufacture and Supply Agreement dated July 27, 2011, the content of which speaks for itself.
`
`25.
`
`Answering Paragraph 25 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 25, and refers to the Manufacture and Supply Agreement, which speaks
`
`for itself.
`
`26.
`
`Answering Paragraph 26 of the Amended Complaint, Dobfar objects that the
`
`allegations in Paragraph 26 are not “simple, concise, and direct” as required under Federal Rule
`
`of Civil Procedure 8(d)(1) and, on that basis, denies the allegations of Paragraph 26. To the
`
`extent that a response by Dobfar is required, Dobfar denies the allegations of Paragraph 26, and
`
`refers to the Manufacture and Supply Agreement, which speaks for itself.
`
`27.
`
`Answering Paragraph 27 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 27, and refers to the Manufacture and Supply Agreement, which speaks
`
`for itself.
`
`
`ny-1154439
`
`- 6 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 6
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 7 of 19 PageID: 3914
`
`
`
`28.
`
`Answering Paragraph 28 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 28, and refers to the Manufacture and Supply Agreement, which speaks
`
`for itself.
`
`29.
`
`Answering Paragraph 29 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 29.
`
`30.
`
`Answering Paragraph 30 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 30 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`31.
`
`Answering Paragraph 31 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 31 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`ANSWER TO FIRST COUNT
`(Denial of Infringement of the ’102 Patent)
`
`32.
`
`Answering Paragraph 32 of the Amended Complaint, Dobfar incorporates its
`
`answers to Paragraphs 1 to 31 as if fully set forth therein.
`
`33.
`
`Answering Paragraph 33 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 33 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 33.
`
`34.
`
`Answering Paragraph 34 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 34 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`
`ny-1154439
`
`- 7 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 7
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 8 of 19 PageID: 3915
`
`
`
`35.
`
`Answering Paragraph 35 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 35 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`36.
`
`Answering Paragraph 36 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 36 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`37.
`
`Answering Paragraph 37 of the Amended Complaint, Dobfar states that
`
`Paragraph 37 consists entirely of legal conclusions that do not require a response, and denies the
`
`allegations of Paragraph 37 to which a response is required, and specifically denies that Dobfar
`
`infringes or will infringe any claim of the ’102 Patent.
`
`38.
`
`Answering Paragraph 38 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 38 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 38.
`
`39.
`
`Answering Paragraph 39 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 39.
`
`40.
`
`Answering Paragraph 40 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 40.
`
`41.
`
`Answering Paragraph 41 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 41.
`
`42.
`
`Answering Paragraph 42 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 42.
`
`
`ny-1154439
`
`- 8 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 8
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 9 of 19 PageID: 3916
`
`
`
`43.
`
`Answering Paragraph 43 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 43.
`
`44.
`
`Answering Paragraph 44 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 44.
`
`ANSWER TO SECOND COUNT
`(Denial of Infringement of the ’291 Patent)
`
`45.
`
`Answering Paragraph 45 of the Amended Complaint, Dobfar incorporates its
`
`answers to Paragraphs 1 to 44 as if fully set forth therein.
`
`46.
`
`Answering Paragraph 46 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 46 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 46.
`
`47.
`
`Answering Paragraph 47 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 47 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`48.
`
`Answering Paragraph 48 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 48 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`49.
`
`Answering Paragraph 49 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 49 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`50.
`
`Answering Paragraph 50 of the Amended Complaint, Dobfar states that
`
`Paragraph 50 consists entirely of legal conclusions that do not require a response, and denies the
`
`
`ny-1154439
`
`- 9 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 9
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 10 of 19 PageID: 3917
`
`
`
`allegations of Paragraph 50 to which a response is required, and specifically denies that Dobfar
`
`infringes or will infringe any claim of the ’291 Patent.
`
`51.
`
`Answering Paragraph 51 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 51 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 51.
`
`52.
`
`Answering Paragraph 52 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 52.
`
`53.
`
`Answering Paragraph 53 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 53.
`
`54.
`
`Answering Paragraph 54 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 54.
`
`55.
`
`Answering Paragraph 55 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 55.
`
`56.
`
`Answering Paragraph 56 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 56.
`
`57.
`
`Answering Paragraph 57 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 57.
`
`ANSWER TO THIRD COUNT
`(Denial of Infringement of the ’524 Patent)
`
`58.
`
`Answering Paragraph 58 of the Amended Complaint, Dobfar incorporates its
`
`answers to Paragraphs 1 to 57 as if fully set forth therein.
`
`59.
`
`Answering Paragraph 59 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 59 are directed to another Defendant and therefore require no response
`
`
`ny-1154439
`
`- 10 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 10
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 11 of 19 PageID: 3918
`
`
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 59.
`
`60.
`
`Answering Paragraph 60 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 60 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`61.
`
`Answering Paragraph 61 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 61 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`62.
`
`Answering Paragraph 62 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 62 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`63.
`
`Answering Paragraph 63 of the Amended Complaint, Dobfar states that
`
`Paragraph 63 consists entirely of legal conclusions that do not require a response, and denies the
`
`allegations of Paragraph 63 to which a response is required, and specifically denies that Dobfar
`
`infringes or will infringe any claim of the ’524 Patent.
`
`64.
`
`Answering Paragraph 64 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 64 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 64.
`
`65.
`
`Answering Paragraph 65 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 65.
`
`66.
`
`Answering Paragraph 66 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 66.
`
`
`ny-1154439
`
`- 11 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 11
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 12 of 19 PageID: 3919
`
`
`
`67.
`
`Answering Paragraph 67 of the Amended Complaint, Dobfar denies the
`
`allegations in Paragraph 67.
`
`68.
`
`Answering Paragraph 68 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 68.
`
`69.
`
`Paragraph 69.
`
`70.
`
`Answering Paragraph 69 of the Amended Complaint, denies the allegations of
`
`Answering Paragraph 70 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 70.
`
`ANSWER TO FOURTH COUNT
`(Denial of Infringement of the ’290 Patent)
`
`71.
`
`Answering Paragraph 71 of the Amended Complaint, Dobfar incorporates its
`
`answers to Paragraphs 1 to 70 as if fully set forth therein.
`
`72.
`
`Answering Paragraph 72 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 72 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 72.
`
`73.
`
`Answering Paragraph 73 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 73 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`74.
`
`Answering Paragraph 74 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 74 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B).
`
`75.
`
`Answering Paragraph 75 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 75 are directed to another Defendant and therefore require no response
`
`
`ny-1154439
`
`- 12 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 12
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 13 of 19 PageID: 3920
`
`
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 75.
`
`76.
`
`Answering Paragraph 76 of the Amended Complaint, Dobfar states that the
`
`allegations in Paragraph 76 are directed to another Defendant and therefore require no response
`
`from Dobfar. See Fed. R. Civ. P. 8(b)(1)(B). To the extent that a response by Dobfar is
`
`required, Dobfar denies the allegations of Paragraph 76.
`
`77.
`
`Answering Paragraph 77 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 77.
`
`78.
`
`Answering Paragraph 78 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 78.
`
`79.
`
`Answering Paragraph 79 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 79.
`
`80.
`
`Answering Paragraph 80 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 80.
`
`81.
`
`Answering Paragraph 81 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 81.
`
`82.
`
`Answering Paragraph 82 of the Amended Complaint, Dobfar denies the
`
`allegations of Paragraph 82.
`
`ANSWER TO PRAYER FOR RELIEF
`
`Dobfar denies that Plaintiffs are entitled to any of the relief requested.
`
`AFFIRMATIVE DEFENSES
`
`
`
`Dobfar asserts the following defenses without prejudice to the denials in the Answer,
`
`without admitting any allegations of the Amended Complaint not otherwise admitted.
`
`
`ny-1154439
`
`- 13 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 13
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 14 of 19 PageID: 3921
`
`
`
`1.
`
`granted.
`
`FIRST DEFENSE
`(Failure to State a Claim)
`
`Plaintiffs’ Amended Complaint fails to state a claim upon which relief can be
`
`SECOND DEFENSE
`(Noninfringement of the ’102 Patent)
`
`2.
`
`Dobfar has not infringed, induced infringement of, or contributed to the
`
`infringement of any valid and enforceable claim of the ’102 Patent.
`
`THIRD DEFENSE
`(Invalidity of the ’102 Patent)
`
`3.
`
`The ’102 Patent, and each claim thereof, is invalid for failing to comply with the
`
`requirements of the patent laws of the United States, particularly with regard to one or more of
`
`the requirements specified in Sections 101, 102, 103, and/or 112 of Title 35 of the United States
`
`Code.
`
`FOURTH DEFENSE
`(Noninfringement of the ’291 Patent)
`
`4.
`
`Dobfar has not infringed, induced infringement of, or contributed to the
`
`infringement of any valid and enforceable claim of the ’291 Patent.
`
`FIFTH DEFENSE
`(Invalidity of the ’291 Patent)
`
`5.
`
`The ’291 Patent, and each claim thereof, is invalid for failing to comply with the
`
`requirements of the patent laws of the United States, particularly with regard to one or more of
`
`the requirements specified in Sections 101, 102, 103, and/or 112 of Title 35 of the United States
`
`Code.
`
`
`ny-1154439
`
`- 14 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 14
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 15 of 19 PageID: 3922
`
`
`
`SIXTH DEFENSE
`(Noninfringement of the ’524 Patent)
`
`6.
`
`Dobfar has not infringed, induced infringement of, or contributed to the
`
`infringement of any valid and enforceable claim of the ’524 Patent.
`
`SEVENTH DEFENSE
`(Invalidity of the ’524 Patent)
`
`7.
`
`The ’524 patent, and each claim thereof, is invalid for failing to comply with the
`
`requirements of the patent laws of the United States, particularly with regard to one or more of
`
`the requirements specified in Sections 101, 102, 103, and/or 112 of Title 35 of the United States
`
`Code.
`
`EIGHTH DEFENSE
`(Lack of Subject Matter Jurisdiction as to the ’290 Patent)
`
`8.
`
`This Court lacks subject matter jurisdiction over Plaintiffs’ claims for
`
`infringement of the ’290 Patent because the ’290 Patent is not listed in the Orange Book in
`
`connection with Cardene® I.V. Premixed Injection.
`
`NINTH DEFENSE
`(Noninfringement of the ’290 Patent)
`
`9.
`
`Dobfar has not infringed, induced infringement of, or contributed to the
`
`infringement of any valid and enforceable claim of the ’290 Patent.
`
`TENTH DEFENSE
`(Invalidity of the ’290 Patent)
`
`10.
`
`The ’290 patent, and each claim thereof, is invalid for failing to comply with the
`
`requirements of the patent laws of the United States, particularly with regard to one or more of
`
`the requirements specified in Sections 101, 102, 103, and/or 112 of Title 35 of the United States
`
`Code.
`
`
`ny-1154439
`
`- 15 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 15
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 16 of 19 PageID: 3923
`
`
`
`ELEVENTH DEFENSE
`(Lack of Standing with Respect to Chiesi USA
` and Cornerstone BioPharma)
`
`11.
`
`On information and belief, Chiesi USA and Cornerstone BioPharma do not have
`
`and have not alleged proper standing to bring any infringement claims against Dobfar on any of
`
`the Patents-in-Suit.
`
`TWELFTH DEFENSE
`(Lack of Personal Jurisdiction)
`
`This Court lacks personal jurisdiction over Dobfar.
`
`
`THIRTEENTH DEFENSE
`(No Recovery of Costs)
`
`Plaintiffs are barred by 35 U.S.C. § 288 from recovering any costs associated with
`
`12.
`
`13.
`
`this action.
`
`RESERVATION OF RIGHTS
`
`As Dobfar’s investigation is ongoing, Dobfar hereby gives notice that it may assert facts
`
`or acts which tend to establish noninfringement, invalidity, unenforceability or which otherwise
`
`constitute a defense under Title 35 of the United States Code as information becomes available
`
`to Dobfar in sufficient detail to assert such a defense.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Dobfar asks this Court to enter judgment in its favor and grant the
`
`following relief:
`
`1. Dismissing with prejudice the entirety of Plaintiffs’ Amended Complaint;
`
`2. Dismissing all remedies and relief sought by Plaintiffs in the Amended
`
`Complaint; and
`
`3. Granting such other and further relief as the Court may deem just and proper.
`
`
`ny-1154439
`
`- 16 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 16
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 17 of 19 PageID: 3924
`
`
`
`
`
` Dated: October 13, 2014
`
`HILL WALLACK LLP
`
`By: /s/ Eric I. Abraham
`Eric I. Abraham
`Christy L. Saveriano
`eia@hillwallack.com
`csaveriano@hillwallack.com
`202 Carnegie Center
`Princeton, New Jersey 08540
`Telephone: (609) 924-0808
`Fax: (609) 452-1888
`
`
`
`
`
`Of Counsel:
`
`MORRISON & FOERSTER LLP
`David C. Doyle (CA Bar No. 70690)
`12531 High Bluff Drive, Suite 100
`San Diego, California 92130-2040
`Telephone: (858) 720-5100
`Fax: (858) 720-5125
`
`Matthew M. D’Amore
`Hui Liu
`Sarah L. Prutzman
`250 West 55th Street
`New York, NY 10019-9601
`Tel: (212) 468-8000
`Fax: (212) 468-7900
`
`Attorneys for Defendant
`ACS Dobfar Info SA
`
`
`
`
`
`ny-1154439
`
`- 17 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 17
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 18 of 19 PageID: 3925
`
`
`
`ACS DOBFAR INFO SA’S LOCAL CIVIL RULE 11.2 CERTIFICATION
`
` I hereby certify that ACS Dobfar Info SA is not a party to any other civil action,
`
`pending arbitration, or administrative proceeding concerning the matter in controversy.
`
`
`Dated: October 13, 2014
`
` /s/ Eric I. Abraham______
` Eric. I. Abraham
`
`
`
`ny-1154439
`
`- 18 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 18
`
`

`
`Case 1:13-cv-05723-NLH-AMD Document 188 Filed 10/13/14 Page 19 of 19 PageID: 3926
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on October 13, 2014, I electronically filed ACS DOBFAR INFO
`
`SA’S ANSWER TO PLAINTIFFS’ AMENDED COMPLAINT with the Clerk of Court using
`
`the CM/ECF system which will also send notification of such filing to the following:
`
`Michael R. Griffinger
`griffinger@gibbonslaw.com
`Gibbons P.C.
`One Gateway Center
`Newark, New Jersey 07102
`Tel: (973) 596-4500
`Fax: (973) 639-6257
`
`Leann Marie Clymer
`lclymer@flhlaw.com
`Frommer Lawrence & Haug LLP
`745 Fifth Avenue
`New York, New York 10151
`Tel: (212) 863-2649
`
`
`
`
`/s/Eric I. Abraham
`Eric I. Abraham
`
`
`ny-1154439
`
`- 19 -
`
`
`
`EKR Therapeutics, LLC Exhibit 2007 Page 19